Annals of Oncology

Annals of Oncology, the official journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, offers rapid and efficient peer-reviewed publications on innovative cancer treatments and translational research in oncology and precision medicine. The journal primarily focuses on areas such as systemic anticancer therapy, with a specific emphasis on molecular targeted agents and new immune therapies. We also welcome randomized trials, including negative results, as well as top-level guidelines. Additionally, we encourage submissions in emerging fields that are crucial to personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Manuscripts related to radiotherapy, surgery, and pediatrics will be considered if they demonstrate a clear interaction with any of the aforementioned fields or if they present groundbreaking findings. Our international editorial board comprises renowned experts who are leaders in their respective fields. Through Annals of Oncology, we strive to provide the most effective communication on the dynamic and ever-evolving global oncology landscape.

《Annals of Oncology》是欧洲肿瘤内科学会和日本肿瘤内科学会的官方期刊，提供有关创新癌症治疗以及肿瘤学和精准医学转化研究的快速、高效的同行评审出版物。 该杂志主要关注系统抗癌治疗等领域，特别强调分子靶向药物和新的免疫疗法。也欢迎随机试验，包括阴性结果以及顶级指南。此外，也鼓励对个性化医疗至关重要的新兴领域提交论文，例如分子病理学、生物信息学、现代统计学和生物技术。如果与放射治疗、外科手术和儿科相关的稿件表现出与上述任何领域有明显的相互作用，或者如果它们提出了突破性的发现，也将被考虑。 该期刊的国际编辑委员会由知名专家组成，他们都是各自领域的领导者。通过《Annals of Oncology》，致力于就动态且不断发展的全球肿瘤学格局提供最有效的沟通。